How melanoma cells evade trail-induced apoptosis

Nature Reviews Cancer

Volumn 1, Issue 2, 2001, Pages 142-150

  Hersey, Peter ^a   Zhang, Xu Dong ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CASP9 PROTEIN, HUMAN; CASPASE; CASPASE 9; CYTOCHROME C; FAS ANTIGEN; FAS LIGAND; FASLG PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; PROTEIN P53; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR PROTEIN;

ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; CELL CULTURE; DNA DAMAGE; DRUG EFFECT; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; IMMUNOLOGY; MACROMOLECULE; MELANOMA; MITOCHONDRION; NATURAL KILLER CELL; PATHOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 9; CASPASES; CYTOCHROME C GROUP; DNA DAMAGE; ENZYME ACTIVATION; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KILLER CELLS, NATURAL; MACROMOLECULAR SUBSTANCES; MAP KINASE SIGNALING SYSTEM; MELANOMA; MEMBRANE GLYCOPROTEINS; MITOCHONDRIA; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NF-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035523826     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/35101078     Document Type: Article

References (28)

1. Martin, D. S., Stolfi, R. L. & Colofiore. J. R. Perspective: the chemotherapeutic relevance of apoptosis and a proposed biochemical cascade for chemotherapeutically induced apoptosis. Cancer Invest. 15, 372-331 (1997). One of several reviews that espouse the idea of a final common pathway to apoptosis despite different biochemical targets.
2. Houghton, J. A. Apoptosis and drug response. Curr. Opin. Oncol. 11, 475-481 (1999).
3. Coultas, L. & Strasser, A. The molecular control of DNA damage-induced cell death. Apoptosis 5, 491-507 (2000).
4. Li, G., Tang, L. Zhou, X., Tron, V. & Ho, V. Chemotherapy-induced apoptosis in melanoma. Melanoma Res. 8, 17-23 (1998).
5. Thomas, W. D. et al. Temozolomide inhibits activation of NF-κB and sensitizes melanoma cells to TRAIL induced apoptosis. Proc. Am. Assoc. Cancer Res. 41, 70 (2000).
6. 6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Clin. Cancer Res. 7, 421-428 (2001).
7. Piccinini, M. et al. Proteasomes are a target of the antitumour drug vinblastine. Biochem. J. 356, 835-841 (2001).
8. Satyamoorthy, K. et al. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ. 11, 467-474 (2000).
9. Rizos, H., Darmanian, A. P., Holland, E. A., Mann, G. J. & Kefford, R. F. Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF. J. Biol. Chem. 2001 Aug 22; [epub ahead of print].
10. Serrone, L. & Hersey, P. The chemoresistance of human malignant melanoma: an update. Melanoma Res. 9, 51-58 (1999).
11. Hersey, P., Murray, E., Grace, J. & McCarthy, W. H. Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma. Pathology 17, 385-391 (1985).
12. Tefany, F. J., Barnetson, R. S., Halliday, G. M., McCarthy, S. W. & McCarthy, W. H. Immunocytochemical analysis of the cellular infiltrate in primary regressing and nonregressing malignant melanoma. J. Invest. Dermatol. 97, 197-202 (1991).
13. Rosenberg, S. A. et al. Treatment of patients with metastatic melanoma with autologous tumour-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst. 86, 1159-1166 (1994).
14. Yee, C. et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192, 1637-1643 (2000).
15. Albertini, M. R. et al. Phase IB trial of chimeric antidisiatoganglioside antibody plus interleukin 2 for melanoma patients. Clin. Cancer Res. 3, 1277-1288 (1997).
16. Trapani, J. A., Sutton, V. R. & Smyth, M. J. CTL granules: evolution of vesicles essential for combating virus infections. Immunol. Today 20, 351-356 (1999).
17. Sutton, V. R. et al. Initiation of apoptosis by granzyme B requires direct cleavage of BID, but not direct granzyme B-mediated caspase activation. J. Exp. Med. 192, 1403-1413 (2000). One of several key articles showing that granzyme B kills target cells by inducing changes in mitochondria.
18. Heibein, J. A. et al. Granzyme B-mediated cytochrome c release is regulated by the BCL2 family members BID and BAX. J. Exp. Med. 192, 1391-1401 (2000).
19. Walczak, H. & Krammer, P. H. The CD95 (APO-1/FAS) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res. 256, 58-66 (2000).
20. Strasser, A., O'Connor, L. & Dixit, V. M. Apoptosis signaling. Annu. Rev. Biochem. 69, 217-245 (2000).
21. + T cells might kill melanoma by TRAIL-dependent mechanisms.
22. Kayagaki, N. et al. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189, 1451-1460 (1999).
23. Griffith, T. S. et al. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL J. Exp. Med. 189, 1343-1353 (1999).
24. Smyth, M. J. et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to Interferon γ-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193, 661-670 (2001).
25. + NKT cells induces in vitro and in vivo apoptosis of human myeloid leukemia cells. Blood 97, 2067-2074 (2001).
26. Fanger, N. A., Maliszewski, C. R., Schcoley, K. & Griffith, T. S. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. 190, 1155-1164 (1999).
27. Takeda, K. et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nature Med. 7, 94-100 (2001).
28. Nguyen, T., Thomas, W., Zhang, X. D., Gray, C. & Hersey, P. Immunologically-mediated tumour cell apoptosis: the role of TRAIL in T cell and cytokine-mediated responses to melanoma. Forum (Geneva) 10, 243-252 (2000). This study shows that IFN-α2 induces TRAIL on T cells from melanoma patients. Induction is less on T cells from patients with advanced disease and can be inhibited by factors released from melanoma cells.